Hardest people to save are ones closest to death. Leronlimab performed the best albeit small sub group but plenty enough data to support except in pvalue fda land. With omicon less severe than delta leronlimab could have even a higher pvalue compared to placebo. Im excited for the trails to fill and get data from Brazil.